Semax: Fast Neurotrophin Signals, Single-Region Evidence

The short version

Semax is a synthetic heptapeptide — seven amino acids — built by taking a fragment of the stress hormone ACTH and grafting a short tripeptide tail onto it. The full name is ACTH(4-7)PGP, but it is known almost universally as Semax. The tail slows enzymatic breakdown. The result is a molecule that, in rat brain, quickly and specifically changes expression of two important growth-supporting proteins: BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor) ^[3][4]. It is registered as a prescription nasal spray for ischemic stroke, transient ischemic attack, cognitive impairment, and optic-nerve disease in Russia and Ukraine.

Here is what this desk will not let go unacknowledged. Nearly all of Semax's mechanistic and efficacy data come from a small number of Russian institutions, and much of the clinical literature is in Russian. There are no published Western randomized controlled trials. The widely reported focus, clarity, and cognitive benefits that appear in community writeups are not backed by clinical evidence in Western populations. This page describes what the studies found, not what users believe.

What it is

Semax is the acetate salt of the linear heptapeptide H-Met-Glu-His-Phe-Pro-Gly-Pro-OH (one-letter code: MEHFPGP). It combines the native ACTH(4-7) fragment (Met-Glu-His-Phe) — the stretch of the adrenocorticotropic hormone thought to carry its memory- and attention-related activity — with a C-terminal Pro-Gly-Pro tripeptide engineered to slow enzymatic degradation. Critically, it lacks the steroidogenic (cortisol-releasing) activity of full-length ACTH, so it does not trigger the adrenal stress-hormone cascade. In the United States and most countries outside Russia and Ukraine it is sold only as an unscheduled research chemical, not a regulated medicine.

How it works

The best-documented molecular effect of Semax in rodent brain is rapid, region-specific neurotrophin regulation. A single intranasal dose in rats changed NGF and BDNF mRNA within hours: BDNF and NGF rose in the hippocampus, BDNF rose in the brainstem and cerebellum, but NGF fell in the frontal cortex — a pattern that is region-specific, not a blanket upregulation ^[3]. Separately, intranasal Semax increased BDNF protein in rat basal forebrain and bound a specific, reversible, calcium-dependent site on brain membranes with a dissociation constant of about 2.4 nM ^[4].

In cerebral ischemia models, the dominant mechanism is less a single receptor action and more a wide immunomodulatory and vascular shift: genome-wide transcriptional analysis after permanent middle-cerebral-artery occlusion in rats found that Semax predominantly altered immune-system genes — immunoglobulins and chemokines — and 24 vascular-system genes, framing its neuroprotection as an inflammatory and vascular effect rather than a direct neuroprotective one ^[2].

Semax also inhibits enkephalin-degrading enzymes in human serum in vitro (IC50 approximately 10 micromolar), which is proposed to prolong endogenous opioid signaling — a mechanism it shares with Selank ^[4]. Its monoaminergic profile is more nuanced than often stated: it raised the serotonin metabolite 5-HIAA in rodents but did not raise baseline dopamine, only potentiating amphetamine-evoked dopamine release. Claims of direct dopamine elevation overstate that evidence.

What the research shows

Neurotrophin regulation in rats. A single 50 micrograms per kilogram intranasal dose produced rapid, gene- and region-specific changes in BDNF and NGF mRNA across rat brain regions ^[3]. A companion study confirmed a specific binding site and a regional increase in BDNF protein in basal forebrain at 3 hours post-dose ^[4].

Neuroprotection and immunomodulation. In a rat permanent MCAO model, Semax predominantly shifted immune-system gene expression — more than half of all affected genes — plus a vascular-gene program, framing its stroke-protective effect as an immunomodulatory and circulatory mechanism rather than a direct antiapoptotic one ^[2].

Ischemia and cognition. Intranasal Semax over 6 days in a rat focal cortical ischemia model decreased infarct volume and preserved retention of a conditioned avoidance response, supporting both the neuroprotective and antiamnesic effects studied clinically in Russia ^[5].

Spinal cord injury. In a 2025 study, Semax improved functional recovery and inhibited pyroptosis in female mice with spinal cord injury by targeting the mu-opioid receptor gene Oprm1 via a USP18/FTO deubiquitination pathway — a mechanistic axis not studied in earlier work ^[1].

Human evidence. This is where the honest picture narrows sharply. Human data are largely from Russian and Ukrainian clinical practice — stroke, cognitive impairment, optic-nerve disease — conducted by a small group of related institutions. There are no published Western randomized controlled trials. The published human work is largely older EEG and clinical reports, not blinded placebo-controlled trials meeting modern standards.

Reported effects, cautions & safety

The following community reports are drawn from nootropic forums, biohacker writeups, and peptide-user communities. They are anecdotal, not clinical evidence, and are kept separate from the cited findings above.

People who respond to Semax most commonly describe a fast, clean mental clarity — thoughts feeling more organized without the wired quality of a stimulant — arriving within the first hour of intranasal use. Very commonly reported alongside this is sustained focus and a 'just keep moving' productivity quality, sometimes described as stimulant-free motivation. Verbal fluency and word recall are occasionally flagged as distinctively improved. Mood lift and stress resilience are commonly mentioned. A meaningful counterweight runs through community discussion: a notable share of users describe the effect as too subtle to be sure it is real, and some report nothing at all. Short duration — a few hours — is one of the most consistent practical observations. Adverse effects commonly reported include nasal burning on intranasal use (very common), afternoon fatigue as the effect fades, and occasional headache. Irritability and potentiation of stimulants are reported by a minority, consistent with the rodent monoaminergic data.

From the cited literature, the key cautions are:

• Unregulated supply. Outside Russia and Ukraine, Semax is a research chemical with no required testing of identity, purity, sterility, or peptide content. Quality varies widely between suppliers, and none of the published pharmacology was done on consumer research-chemical product ^[4].
• Single-tradition evidence base. Almost all human experience and clinical evidence comes from Russian and Ukrainian institutions. The bulk of mechanistic data is rodent. Long-term safety in healthy people using it as a nootropic is essentially uncharacterized in independent literature.
• Neurotrophin and gene-expression effects are not trivial. Semax rapidly and region-specifically changes expression of BDNF, NGF, and — in injury models — large numbers of immune and vascular genes ^[2][3]. The consequences of repeatedly driving neurotrophin expression in a healthy human brain over months or years have not been studied.
• Unknown drug interactions. Semax inhibits enkephalin-degrading enzymes and strongly potentiates amphetamine-evoked dopamine release in rodents. Combining it with stimulants, serotonergic drugs, or opioid-active compounds has unstudied and potentially additive effects. Community reports of anxiety and irritability when stacked with caffeine or ADHD medication are mechanistically consistent with this.
• No established human dosing framework. All quantitative dosing in the literature is from animal studies. There is no validated human dosing schedule outside Russian clinical formulations.

Where it fits in cognitive research

Among the three peptides on this desk, Semax is the most active and the most mechanistically characterized — but active and well-characterized in a specific context: rodent brain and Russian clinical medicine. Its neurotrophin-signaling and immunomodulatory mechanisms are genuinely interesting; what is missing is independent Western replication in controlled trials. Community reports suggest a real-world focus and clarity effect for a meaningful share of users, but that is not the same as clinical evidence, and a real share of users report nothing at all. Read alongside Selank, which has the most human data here, and DSIP, which has the least mechanistic resolution of the three. See the comparison page for how they line up.